For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory decisions, and disruptive inn ...

For many, it begins quite simply. Maybe it was a party, a music event, or just clicking online. They access what seems like a ...

In a twist, researchers at the University of Virginia and the National Institutes of Health uncovered a new organelle, dubbed ...

A newly found organelle, the hemifusome, helps manage cellular recycling. It may play a role in inherited diseases and open ...

Even after decades of research, biologists are still uncovering surprises about the human body. A team of researchers from ...

Historical Perspective Published: May 1999 A unifying concept: the history of cell theory Paolo Mazzarello Nature Cell Biology 1, E13–E15 (1999) Cite this article ...

Nature Reviews Molecular Cell Biology - Structure WatchStructure Watch Published: February 2003 Structure Watch Nature Reviews Molecular Cell Biology 4, 87 (2003) Cite this article ...

Private Equity Fund Structure Private equity funds can engage in leveraged buyouts (LBOs), mezzanine debt, private placement loans, and distressed debt, or they can serve in the portfolio of a ...

The Natural History of Generalized Anxiety Disorder: A Review Catherine L. Woodman, MD Disclosures Medscape Psychiatry & Mental Health eJournal. 1997;2 (3) 0 ...

Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children undergoing HSCT.